Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
148.35(c) 148.89(c) 148.4(c) 147.17(c) 149.18(c) Last
4 375 798 3 659 221 4 323 502 5 461 414 12 030 855 Volume
+0.39% +0.36% -0.33% -0.83% +1.37% Change
More quotes
Financials (USD)
Sales 2020 80 541 M - -
Net income 2020 16 242 M - -
Net Debt 2020 3 827 M - -
P/E ratio 2020 24,5x
Yield 2020 2,69%
Sales 2021 87 437 M - -
Net income 2021 21 537 M - -
Net cash position 2021 7 225 M - -
P/E ratio 2021 18,4x
Yield 2021 2,83%
Capitalization 393 B 393 B -
EV / Sales 2020 4,92x
EV / Sales 2021 4,41x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (51.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (31.6%): diagnostic systems, orthopedic... 
Sector
Pharmaceuticals
Calendar
09/21 | 01:05pmPräsentation
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
09/18Five leading health care companies lost over $65 billion in market cap YTD
AQ
09/17JOHNSON & JOHNSON : NY Files Charges Against J&J Over Opioids -- 2nd Update
DJ
09/17JOHNSON & JOHNSON : NY Files Charges Against J&J Over Opioids -- Update
DJ
09/17JOHNSON & JOHNSON : NY Files Charges Against J&J Over Opioids
DJ
09/17Developing Countries Push to Limit Patent Protections for Covid Vaccines
DJ
09/16MOMENTA PHARMACEUTICALS : Announces Expiration of Hart-Scott-Rodino Waiting Peri..
AQ
09/15JOHNSON & JOHNSON : to Host Investor Conference Call on Third-Quarter Results
AQ
09/15CALL FOR AWARD APPLICANTS : Johnson & Johnson Seeks Female Researchers Working i..
AQ
09/14JOHNSON & JOHNSON : OPL 245 - Malami Breaks Silence On 35% Asset Recovery Fee De..
AQ
09/14JOHNSON & JOHNSON : Janssen to Present Key Data from Across Its Expansive Oncolo..
PU
09/14JOHNSON & JOHNSON : Janssen Highlights Impact of Multiple Sclerosis-Related Fati..
AQ
09/14SPRINGWORKS THERAPEUTICS : in Clinical Collaboration With Janssen Biotech
DJ
09/12JOHNSON & JOHNSON : Govt Silent As Nigeria Risks Losing Huge Sums in Opaque Mala..
AQ
09/11JOHNSON & JOHNSON : Janssen Highlights Impact of Multiple Sclerosis-Related Fati..
PU
09/11JOHNSON & JOHNSON : Medical Devices Companies Launches 'My Health Can't Wait' To..
AQ
More news
News in other languages on JOHNSON & JOHNSON
09/18SANOFI/GSK : Bruxelles signe un deuxième contrat pour l'accès à un vaccin contre..
09/10COVID-19 : plus de 900.000 morts, mauvaise nouvelle sur le front du vaccin
09/09COVID-19 : l'UE réserve 200 millions de doses du potentiel vaccin Biontech/Pfize..
09/09CORONA-IMPFSTOFF : EU will von Biontech bis zu 300 Millionen Dosen
09/01CORONAVIRUS : le point sur la pandémie
More news
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 162,89 $
Last Close Price 149,18 $
Spread / Highest target 20,7%
Spread / Average Target 9,19%
Spread / Lowest Target -5,48%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.27%392 765
ROCHE HOLDING AG9.27%322 209
MERCK & CO., INC.-5.65%217 034
PFIZER, INC.-6.02%203 549
NOVARTIS AG-9.76%200 978
NOVO NORDISK A/S12.50%161 415